Peddock Capital Advisors LLC Sells 248 Shares of CVS Health Corp (NYSE:CVS)

Peddock Capital Advisors LLC cut its stake in CVS Health Corp (NYSE:CVS) by 1.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,918 shares of the pharmacy operator’s stock after selling 248 shares during the quarter. Peddock Capital Advisors LLC’s holdings in CVS Health were worth $813,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CVS. Capital Investment Advisory Services LLC increased its stake in shares of CVS Health by 3.8% during the first quarter. Capital Investment Advisory Services LLC now owns 5,128 shares of the pharmacy operator’s stock valued at $277,000 after buying an additional 189 shares during the period. Virginia National Bank increased its stake in shares of CVS Health by 4.9% during the first quarter. Virginia National Bank now owns 4,100 shares of the pharmacy operator’s stock valued at $221,000 after buying an additional 190 shares during the period. Burke & Herbert Bank & Trust Co. increased its stake in shares of CVS Health by 2.8% during the first quarter. Burke & Herbert Bank & Trust Co. now owns 7,466 shares of the pharmacy operator’s stock valued at $402,000 after buying an additional 200 shares during the period. Fiduciary Group LLC increased its stake in shares of CVS Health by 3.2% during the second quarter. Fiduciary Group LLC now owns 6,485 shares of the pharmacy operator’s stock valued at $353,000 after buying an additional 200 shares during the period. Finally, First Command Financial Services Inc. increased its stake in shares of CVS Health by 16.0% during the second quarter. First Command Financial Services Inc. now owns 1,464 shares of the pharmacy operator’s stock valued at $80,000 after buying an additional 202 shares during the period. Institutional investors own 75.20% of the company’s stock.

CVS stock traded up $0.09 during trading on Thursday, reaching $61.74. 2,768,770 shares of the company traded hands, compared to its average volume of 9,125,229. CVS Health Corp has a 12 month low of $51.72 and a 12 month high of $82.15. The business has a 50 day simple moving average of $57.08 and a 200 day simple moving average of $56.37. The company has a market capitalization of $79.84 billion, a price-to-earnings ratio of 8.72, a price-to-earnings-growth ratio of 1.35 and a beta of 0.90. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.64 and a current ratio of 0.95.



CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.70 by $0.19. The company had revenue of $63.43 billion for the quarter, compared to the consensus estimate of $62.66 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. The firm’s revenue for the quarter was up 35.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.69 earnings per share. As a group, research analysts forecast that CVS Health Corp will post 6.96 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, August 2nd. Shareholders of record on Thursday, July 25th were issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 3.24%. The ex-dividend date was Wednesday, July 24th. CVS Health’s dividend payout ratio is presently 28.25%.

Several equities analysts have recently commented on CVS shares. Evercore ISI set a $63.00 price target on CVS Health and gave the company a “buy” rating in a research note on Wednesday, August 7th. Morgan Stanley restated a “buy” rating and set a $74.00 price target on shares of CVS Health in a research note on Sunday, August 11th. ValuEngine lowered CVS Health from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 2nd. BMO Capital Markets set a $63.00 price target on CVS Health and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Standpoint Research upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Wednesday, June 5th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $75.14.

About CVS Health

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Recommended Story: Does a trade war provide a risk to the global economy?

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.